August 21st, 2011 by GarySchwitzer in News, Opinion
No Comments »
Right off the top, let me be clear that I am NOT minimizing the importance of this week’s news about an experimental treatment for leukemia – one that has drawn much news attention.
It is an important finding.
What I am commenting on herein is the news coverage.
The ABC television piece itself wasn’t bad, with good perspective from Dr. Len Lichtenfeld of the American Cancer Society. But the lead-in and the ending, both involving anchor Diane Sawyer, were hyperbolic. The following screenshot was part of Sawyer’s lead-in. Read more »
*This blog post was originally published at Gary Schwitzer's HealthNewsReview Blog*
August 16th, 2011 by Elaine Schattner, M.D. in News, Opinion
2 Comments »
Last Sunday’s New York Times featured an op-ed by Dr. Ezekiel Emanuel, on the oncology drug shortage. It’s a serious problem that’s had too-little attention in the press:
Of the 34 generic cancer drugs on the market, as of this month, 14 were in short supply. They include drugs that are the mainstay of treatment regimens used to cure leukemia, lymphoma and testicular cancer.
Emanuel considers that these cancer drug shortages have led to what amounts to an accidental rationing of cancer meds. Some desperate and/or influential patients (or doctors or hospitals) get their planned chemo and the rest, well, don’t.
Unfortunately, Read more »
*This blog post was originally published at Medical Lessons*
August 10th, 2011 by Michael Kirsch, M.D. in Health Policy, Opinion
2 Comments »
The concept of cost-effectiveness in medicine is elastic. One’s view on this issue depends upon who is paying the cost. Of course, this is true in all spheres of life. When you’re in a fine restaurant, you order differently when the meal will be charged to someone else. Under these circumstances, the foie gras appetizer and the jumbo shrimp cocktail are no longer luxuries, but are considered as essential amino acids that are necessary to maintain life.
In the marketplace, except in the medical universe, goods and services are priced according to what the market will bear. If an item is priced too high, then the seller will have fewer sales and a bloated inventory. Consumers will not pay absurd prices for common items, regardless of supernatural claims of quality.
- Would you pay $100 for an ice cream sundae that boasted it was the best in the world?
- Would you pay $1000 for a tennis racket that promised performance beyond your ability?
- Would you pay $500 for a box of paper clips that never lose their tension? Read more »
*This blog post was originally published at MD Whistleblower*
August 9th, 2011 by Elaine Schattner, M.D. in Opinion, Research
No Comments »
We’ve reached the second half of our discussion on Bending the Cost Curve in Cancer Care. The authors of the NEJM paper, Drs. T. Smith and B. Hillner, go on to consider how doctors’ behavior influences costs in Changing Attitudes and Practice. Today’s point on the list: “Oncologists need to recognize that the costs of care are driven by what we do and what we do not do.”
In other words (theirs): “The first step is a frank acknowledgment that changes are needed.” A bit AA-ish, but fair enough –
The authors talk about needed, frank discussions between doctors and patients. They emphasize that oncologists/docs drive up costs and provide poorer care by failing to talk with patients about the possibility of death, end-of-life care, and transitions in the focus of care from curative intent to palliation.
They review published findings on the topic: Read more »
*This blog post was originally published at Medical Lessons*
July 18th, 2011 by Elaine Schattner, M.D. in Opinion, Research
No Comments »
Yesterday’s post was not really about Avastin, but about medical journalism and how patients’ voices are handled by the media.
L. Husten, writing on a Forbes blog, cried that the press fawned, inappropriately, over patients’ words at the FDA hearing last week, and that led him to wonder why and if journalists should pay attention to what people with illness have to say, even if their words go against the prevailing medical wisdom.
There’s a fair amount of controversy on this. For sake of better discussion in the future, I think it best to break it up into 3 distinct but inter-related issues:
1. About health care journalism and patients’ voices:
A general problem I perceive (and part of why I started blogging) is how traditional medical journalists use patients’ stories to make a point. What some of my journalism professors tried to teach me, and most editors I’ve dealt with clearly want, is for the reporter to find a person with an illness, as a lead, and then tell about the relevant news, and provide some expert commentary – with at least one person speaking on each “side” of the issue, of course – and then end the story with some bit about the patient and the future.
I argue that this form of medical journalism Read more »
*This blog post was originally published at Medical Lessons*
